IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study
Zhang, X. W.1; Li, Chun1; Ma, X. X.1; Zhao, J. X.2; An, Yuan1; Liu, Shuang1; Li, Yan1; Li, Z. G.1
关键词Cyclophosphamide Lupus nephritis Menstrual disturbance
刊名CLINICAL RHEUMATOLOGY
2014-07-01
DOI10.1007/s10067-014-2590-6
33期:7页:939-945
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Rheumatology
研究领域[WOS]Rheumatology
关键词[WOS]RANDOMIZED CONTROLLED-TRIAL ; OVARIAN FAILURE ; IMMUNOSUPPRESSIVE THERAPY ; PULSE CYCLOPHOSPHAMIDE ; MYCOPHENOLATE-MOFETIL ; ERYTHEMATOSUS ; AZATHIOPRINE ; PREDNISOLONE ; GLOMERULONEPHRITIS ; METHYLPREDNISOLONE
英文摘要

Cyclophosphamide (CYC) has long been considered a gold standard in inducing renal remission and preventing renal flares for patients with systemic lupus erythematosus (SLE). However, the rational use of CYC has not reached a consensus, such as the timing and length of treatment, the route of administration, and the ideal dosage. The objective of this study was to assess the efficacy and safety of short-interval lower-dose (SILD) intravenous (IV) CYC in the treatment of SLE. A total of 225 patients with lupus nephritis were randomly assigned to a 1-year trial, either the SILD group (12 fortnightly pulses at a fixed dose of 400 mg followed by 6 monthly pulses) or high-dose (HD) group (6 monthly pulses followed by two quarterly pulses at a dose of 0.5 similar to 1.0 g/m(2)). At 6 months of treatment, 28 % (30/107) of patients in the SILD group reached a complete remission (CR), and 51.4 % (55/107) were in partial remission (PR), as compared with 32.7 % (35/107) and 45.8 % (49/107) in the HD group, respectively. Serum albumin, 24-h urinary protein, and the scores of disease activity were significantly improved in both groups at 6 months and maintained at the end of clinical trial. However, the SILD group showed much less menstrual disturbances (11.5 %), gastrointestinal adverse effects (5.3 %), and leukopenia (9.7 %) than the HD group (28.6, 26.8, and 19.8 %, respectively) at the end of clinical trial. The efficacy of the short-interval lower-dose (SILD) IV CYC regimen in the treatment of lupus nephritis is equivalent to that of the high-dose (HD) regimen, whereas the incidence of adverse events is much lower in the SILD group.

语种英语
WOS记录号WOS:000338324000009
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65052
专题北京大学第二临床医学院
北京大学第二临床医学院_风湿免疫科
作者单位1.Peking Univ, Peoples Hosp, Dept Rheumatol & Immunol, Beijing 100044, Peoples R China
2.Peking Univ, Hosp 3, Dept Rheumatol & Immunol, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Zhang, X. W.,Li, Chun,Ma, X. X.,et al. Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study[J]. CLINICAL RHEUMATOLOGY,2014,33(7):939-945.
APA Zhang, X. W..,Li, Chun.,Ma, X. X..,Zhao, J. X..,An, Yuan.,...&Li, Z. G..(2014).Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study.CLINICAL RHEUMATOLOGY,33(7),939-945.
MLA Zhang, X. W.,et al."Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study".CLINICAL RHEUMATOLOGY 33.7(2014):939-945.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, X. W.]的文章
[Li, Chun]的文章
[Ma, X. X.]的文章
百度学术
百度学术中相似的文章
[Zhang, X. W.]的文章
[Li, Chun]的文章
[Ma, X. X.]的文章
必应学术
必应学术中相似的文章
[Zhang, X. W.]的文章
[Li, Chun]的文章
[Ma, X. X.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。